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Abstract
Background: Their large scaffold diversity and properties, such as structural complexity and drug similarity, form the basis of
claims that natural products are ideal starting points for drug design and development. Consequently, there has been great
interest in determining whether such molecules show biological activity toward protein targets of pharmacological
relevance. One target of particular interest is hIKK-2, a serine-threonine protein kinase belonging to the IKK complex that is
the primary component responsible for activating NF-kB in response to various inflammatory stimuli. Indeed, this has led to
the development of synthetic ATP-competitive inhibitors for hIKK-2. Therefore, the main goals of this study were (a) to use
virtual screening to identify potential hIKK-2 inhibitors of natural origin that compete with ATP and (b) to evaluate the
reliability of our virtual-screening protocol by experimentally testing the in vitro activity of selected natural-product hits.
Methodology/Principal Findings: We thus predicted that 1,061 out of the 89,425 natural products present in the studied
database would inhibit hIKK-2 with good ADMET properties. Notably, when these 1,061 molecules were merged with the 98
synthetic hIKK-2 inhibitors used in this study and the resulting set was classified into ten clusters according to chemical
similarity, there were three clusters that contained only natural products. Five molecules from these three clusters (for which
no anti-inflammatory activity has been previously described) were then selected for in vitro activity testing, in which three
out of the five molecules were shown to inhibit hIKK-2.
Conclusions/Significance: We demonstrated that our virtual-screening protocol was successful in identifying lead
compounds for developing new inhibitors for hIKK-2, a target of great interest in medicinal chemistry. Additionally, all the
tools developed during the current study (i.e., the homology model for the hIKK-2 kinase domain and the pharmacophore)
will be made available to interested readers upon request.
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Introduction
Natural products (NPs) are a valuable source of inspiration as
lead compounds for the design and development of new drug
candidates [1]. In fact, over 60% of the current anticancer drugs
are natural-product-related molecules (i.e., either NPs or deriva-
tives/analogues that have been inspired by a natural compound)
[2]. This trend is a direct consequence of the large scaffold
diversity of these molecules [2–4], which, together with properties
such as structural complexity and drug similarity, support the
claim that they are ideal starting points for medicinal chemistry
[2,5]. Despite these clear advantages, it is estimated that only 5 to
15% of the approximately 250,000 described higher plant species
have been tested for some type of biological activity [4] (and the
use of other organisms such as micro-organisms, insects, fungi or
marine species for this aim is just beginning) [6,7]. It has recently
been suggested that bioinformatics/chemoinformatics tools could
be used to screen large NP databases and so identify new bioactive
molecules for specific targets [1,4,8]. One target of interest for NPs
is the human inhibitor nuclear-factor kB kinase 2 (hIKK-2). This
target is a serine-threonine protein kinase belonging to the IKK
complex and is the primary component responsible for activating
the nuclear-factor kB transcription factor (NF-kB) in response to
inflammatory stimuli. Indeed, the importance of the NF-kB
pathway in regulating the expression of the genes controlling
cellular immune and inflammatory responses has motivated
research groups in both academia and the pharmaceutical
industry to devote increasing efforts toward developing synthetic
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16903ATP-competitive inhibitors for hIKK-2 [9–36], which could be of
therapeutic use, e.g., in patients affected by chronic inflammatory
diseases [37].
The hIKK-2 subunit is a polypeptide of 756 residues with a
kinase domain in its 15–300 sequence segment. At present, there
are only two entries in the Protein Data Bank (http://www.pdb.
org; PDB) [38] for hIKK-2 (i.e., PDB codes 3BRT and 3BRV),
and in both cases, they correspond to the NEMO-binding region
located at the C-terminal end of the protein [39] (therefore, no
experimental structure for the kinase domain of hIKK-2 is known).
Moreover, obtaining a homology model for this kinase domain is
not trivial because the more similar protein in the PDB (i.e., the
catalytic domain of human ZIP kinase; PDB code 1YRP) has a
pairwise sequence alignment with hIKK-2 of only 217 residues
long, with a low percentage of sequence identity (i.e., 32%).
Despite this limitation, the great pharmacological interest of this
target has led scientists to develop either ligand-based approaches
[14,40–42] or homology models for this domain [13–
16,19,27,35,42–44] and to use them in virtual-screening (VS) or
drug-design projects. Unfortunately, these pharmacophore hy-
potheses or homology models are not in the public domain.
Therefore, the main goals of this study were to (a) use VS to
identify potential hIKK-2 inhibitors of natural origin that can
compete with ATP and (b) evaluate the reliability of our VS
protocol by experimentally testing the in vitro activity of selected
NP hits. To achieve these goals, we (1) developed a homology
model for the hIKK-2 kinase domain which could stand the test of
our validation criteria, (2) docked ATP-competitive molecules
known to be potent and specific inhibitors of hIKK-2 with this
model [10,11,13,15,16,18,20–31], (3) identified which of the
resulting poses were knowledge-based coherent by analyzing whether
they satisfied the experimentally known generic binding features of
ATP-competitive inhibitors of kinases [45], (4) used the
knowledge-based coherent poses to derive a structure-based
common pharmacophore containing the key intermolecular
interactions between hIKK-2 and its inhibitors, (5) obtained
exclusion volumes from our homology model and added them to
the pharmacophore, (6) validated the selectivity of the resulting
pharmacophore and of the VS process using a large database of
kinase decoys [46] and ATP-competitive inhibitors for hIKK-2
that were not used during the pharmacophore building [47], (7)
used the previously validated structure-based pharmacophore and
VS protocol to find ATP-competitive inhibitors for hIKK-2 in a
database of NPs [48], and, finally, (8) proved the reliability of the
prediction by testing the inhibitory effect of some selected hits on
hIKK-2 in vitro. In addition, all the tools developed during the
current study (i.e., the homology model for the hIKK-2 kinase
domain and the pharmacophore) are available to interested
readers upon request.
Results and Discussion
Homology-model description
The protein kinase domains have a common fold consisting of
two lobes linked by a flexible hinge region (see Figure 1A). Thus,
the N-terminal lobe (from Trp15 to Ala95 in hIKK-2) is formed
by a b-sheet (consisting of five antiparallel b-strands) and an a-
helix that contains Glu61, which is one of the most important
residues when hIKK-2 is in the active form because it makes
polar contacts with the catalytic residue Lys44 (located in b3)
[49,50]. The N lobe also contains the highly conserved
GXGXXG motif called the glycine-rich loop (G-loop) or P-loop,
corresponding to the Gly22-Thr23-Gly24-Gly25-Phe26-Gly27
sequence segment in hIKK-2.
The C-terminal lobe (from Gln100 to Phe300 in hIKK-2) is
highly helical and contains the activation segment formed by the
HRD motif and the activation and catalytic loops. The HRD
motif (from His143 to Asp145 in hIKK-2) is highly conserved in
the kinases, and its arginine residue acts as the catalytic base that
drives the phosphorylation event [50,51]. The activation loop (A-
loop; from Lys171 to Leu189 in hIKK-2) is the most flexible and
diverse part of the activation segment [50] and includes residue(s)
that when phosphorylated enable activity in many kinases (Ser177
and Ser181 for hIKK-2) [49,52]. Finally, the catalytic loop (from
Ile165 to Ala170 in hIKK-2) contains the DFG motif (but Asp166,
Leu167 and Gly168 for hIKK-2) in most kinases, and its Asp
residue forms polar contacts with all three ATP phosphates (either
directly or through coordinating magnesium atoms).
The ATP binding site is a narrow, hydrophobic pocket located
between the two lobes; its floor is formed by a C-terminal b-sheet,
and its roof is formed by the G-loop, which fastens the c-
phosphate of ATP and serves as a regulatory flap above the ATP-
binding site [45,51,53–55].
The most important residue in the hinge region of the protein
kinase domain (from Met96 to Cys99 in hIKK-2) is the gatekeeper
(i.e., Met96 in hIKK-2) [18], which is located behind the
hydrophobic pocket of the ATP-binding site. In that location,
the size or volume of the side chain dictates its access to this pocket
and therefore defines the potential inhibitor selectivity of the ATP-
binding site. Moreover, this hinge region usually has a hydrogen
donor flanked by hydrogen acceptors derived from the protein
backbone, where they form a characteristic hydrogen-bond motif
(in fact, the hinge region provides the most important hydrogen
bonds with the ATP-site inhibitors). The residues involved in this
hydrogen-bond motif are Glu97 and Cys99 in hIKK-2 (called
gk+1 and gk+3 considering their relative location to the gatekeeper
residue, i.e., gk, in the hIKK-2 sequence) [18].
Figure 1B shows the multiple sequence alignment used to guide
the modeling of the best 3D structure obtained for the hIKK-2
kinase domain, which is shown in Figure 1A. Because we were
interested in finding new ATP-competitive inhibitors for hIKK-2,
we selected two kinase structures as templates (2CN5 [56] and
2J90 [57]), each cocrystallized with a different ATP-competitive
inhibitor (ADP and pyridone 6, respectively), both sharing a 32%
sequence identity with the kinase domain of hIKK-2 and a 50%
identity with the residues of the ATP-binding site of hIKK-2
(where these residues correspond to those in the G-loop, hinge
region, HRD motif and catalytic loop).
The Ramachandran plot of this hIKK-2 homology model (see
Figure 1C) shows that only 2.5% of the non-glycine residues (i.e.,
Asn89, Gln110, Cys114, Arg144, Leu160, Thr185, Leu189 and
Ala190) are in disallowed regions. Remarkably, none of these
residues are located in the ATP-binding-site area and, therefore,
its incorrect conformation did not affect our protein-ligand
docking results. Moreover, when the ANOLEA results for the
hIKK-2 model are compared with those for the two templates (see
Table 1), the results show that the packing quality of our homology
model is comparable to the packing qualities of the templates.
Thus, although ANOLEA reports that 8 out of the 22 hIKK-2
high-energy residues (i.e., from Phe182 to Leu189) are located in
the A-loop (a very important area for kinase activity), it also shows
that the equivalent residues in the two template structures also
have high energies. The rest of high-energy residues in the hIKK-
2 homology model are located in areas that are not crucial for its
activity or structural stability.
Finally, the quality of this homology model was tested by using it
as a rigid receptor in protein-ligand docking experiments with
known hIKK-2 inhibitors and evaluating whether the docking
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important for kinase inhibitors, specifically, those with key residues
in the hIKK-2 ATP binding pocket [13,14,44,45,53,58,59]. Thus,
36 known inhibitors of hIKK-2 (listed in Table S1) were docked
with our hIKK-2 homology model without imposing constrains
that forced poses to make specific intermolecular interactions with
the target. Next, the resultant hIKK-2 complexes were analyzed
with the help of LigandScout to determine which complexes
exhibit target-inhibitor intermolecular interactions equivalent to
those described in prior studies [14,15,31,44]. This knowledge-
based analysis enabled us to find at least one knowledge-based
coherent pose for 21 out of the 36 hIKK-2 inhibitors assayed
(regardless of their eHiTS scores). Therefore, we concluded that
(a) our best homology model correctly describes the ATP binding
pocket in hIKK-2 (see Figures 2A and 2B) and (b) our protein-
ligand docking strategy (using the hIKK-2 homology model as a
rigid body and only allowing rotation around ligand single bonds
of the ligand) is valid for describing the interactions between a
large number of known selective ATP-competitive hIKK-2
inhibitors from different chemical families and this target. Notably,
this fast protein-ligand docking strategy is appropriate for use in a
VS workflow, where other more sophisticated and accurate
protein-ligand docking strategies, such as induced-fit docking,
are inapplicable [44].
Figure 1. The homology model for the the kinase domain of hIKK-2. The best homology model for the kinase domain of hIKK-2 obtained in
our study (Figure 1A), the multiple sequence alignment used to guide its modeling (Figure 1B) and its Ramachandran plot (Figure 1C). The relative
locations of the G-loop, hinge region, HRD motif, catalytic loop and A-loop are shown in the model and in the sequence multialignment (using boxes)
with the same color schema (i.e., G-loop in blue; hinge region in cyan; HRD motif in red; catalytic loop in magenta and A-loop in green). The residues
in the alignment are colored according to residue similarity. Circles in the Ramachandran plot show the location of non-glycine residues.
doi:10.1371/journal.pone.0016903.g001
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coherent docking poses for four selected hIKK-2 inhibitors [i.e., 13
[27] (Figure 2C), 12 [18] (Figure 2D), 4a [23] (Figure 2E) and 14
[18] (Figure 2F)] that (a) belong to three different chemical
families [inhibitors 14 [18] (Figure 2F) and 12 [18] (Figure 2D)
share the same structural scaffold], (b) have different types of
intermolecular interactions with the target and (c) share some of
the hIKK-2 residues with which they interact (for instance, all of
Table 1. ANOLEA results for the two templates (2CN5 and 2J90) and the hIKK-2 homology model.
2CN5A 2J90A hIKK-2
Total amino acids with high energy (percentage) 22 (7.77) 31 (11.79) 22 (7.33)
Total number of non-local atomic interactions 32310 30226 33992
Total non-local energy of the protein (E/kT units) 21878 21946 21956
Non-local normalized energy Z-score 0.04 20.49 0.09
doi:10.1371/journal.pone.0016903.t001
Figure 2. The ATP-binding site, the structure-based common pharmacophore and the best poses for different hIKK-2 inhibitors. The
ATP-binding site (Figure 2A), the structure-based common pharmacophore (Figure 2B) and the best poses of the various chemical hIKK-2 inhibitors
that were used during the homology-model validation and the structure-based common pharmacophore construction (Figures 2C, 2D, 2E and 2F). In
Figures 2C, 2D, 2E and 2F, hydrogen-bond donors, hydrogen-bond acceptors and hydrophobic interactions are shown as red arrows, green arrows
and yellow spheres, respectively. Figure 2A shows the ATP-binding pocket of our hIKK-2 homology model and the best poses obtained when docking
it with the hIKK-2 inhibitors 13 [27]; 12 [18]; 4a [23] and 14 [18]. Figure 2B shows the locations on the ATP-binding site of the sites that form the
structure-based common pharmacophore developed in the present work and the shell of excluded volumes (in yellow) that schematically represents
the locations of the surrounding residues. This pharmacophore is formed by two hydrogen-bond donors (in blue), one hydrogen-bond acceptor (in
red) and one hydrophobic region (in green), with tolerances (i.e., radii) of 1.5, 1.5 and 3.0 A ˚, respectively. Figures 2C, 2D, 2E and 2F show the
intermolecular interactions between hIKK-2 and the best poses from inhibitors 13, 12, 4a and 14, respectively. Figures 2A and 2B were drawn with
Maestro v9.0.211 (Schro ¨dinger LLC., Portland, USA; http://www.schrodinger.com), whereas Figures 2C, 2D, 2E and 2F were drawn with LigandScout
v2.03.
doi:10.1371/journal.pone.0016903.g002
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and a hydrophobic interaction with Val29). Thus, the analysis of
this figure revealed the following:
N Inhibitor 13 [27] (see Figure 2C) is a thiophene carboxamide
with substituted ureas that exhibits the most fundamental
intermolecular interactions with the target: (a) hydrogen
bonding between the urea groups and the main-chain oxygens
from Glu97 and Cys99 [27,28,31] in the hinge region (and also
between the carbonyl oxygen atom from 13 and the thiol
group from Cys99) and (b) hydrophobic interaction with
residues Val29, Lys44 and Ile165.
N Inhibitor 12 [18] (see Figure 2D) is an azaindole sulfonamide
that exhibits more hydrogen bonds with hIKK-2 than the
other inhibitors. Specifically, it has (a) two hydrogen bonds
between the two nitrogen atoms from the azaindole ring and
the main-chain N and O from Cys99 (in agreement with the
results of Liddle et al. [18]), (b) one hydrogen bond between its
amide group and the side-chain hydroxyl group of Tyr98, (c)
one hydrogen bond between the nitrogen from the amide
group and the backbone oxygen atom of Gln100, and (d) one
hydrogen bond on the other side of the binding pocket with the
Asn150 and Asp166 side chains. Here, we note that the
relevance of Cys99 and Gln100 in this intermolecular
interaction has been reported [18]. Furthermore, inhibitor
12 has hydrophobic interactions with the Leu21, Val29,
Ala42, Asp145, Val152 and Ile165 side chains.
N Inhibitor 4a [23] (Figure 2E) is a pyridine derivate that has a
very different chemical scaffold than the other inhibitors
studied and, moreover, it belongs to a family of very active
hIKK-2 inhibitors. The Cys99 backbone atoms are involved in
two hydrogen-bonding interactions, one of which is between
the nitrogen and the hydroxyl group in the 29 position of the
benzyl moiety of 4a (which is an important group for this
family of hIKK-2 inhibitors [22–24,37]) and the other is
between the carbonyl oxygen and one of two amine group of
4a. Asp103 also contributes to stabilizing inhibitor 4a on the
other side of the ATP pocket (close to the solvent-accessibility
region of the binding site) by forming another hydrogen bond
between its side-chain oxygen, which accepts the hydrogen
from the second 4a amine group. The theoretical complex also
shows that Val29, Ala42, Val74 and Met96 have hydrophobic
interactions with the 4a benzyl ring.
N Inhibitor 14 [18] (Figure 2F) and inhibitor 12 (Figure 2D)
share the same structural scaffold but have different residue
interactions with the hIKK-2 homology model. Thus, only one
residue in the hinge region (Cys99) forms a hydrogen bond
with 14 (instead of the three hydrogen bonds made by 12; see
above). Here, the hydrogen bond is between the Cys99
carbonyl oxygen and the nitrogen from the azaindole six-
membered ring of 14. Additionally, the amine group of 14
forms a hydrogen bond with the Thr23 hydroxyl group
(located in the G-loop). The hydrophobic interactions of 14
are with Leu21, Val29, Ala42, Val74, Met96, Tyr98, Val152
and Ile165.
Structure-based pharmacophore description
The validation of the homology model for hIKK-2 showed that
our protein-ligand docking strategy found 43 knowledge-based
coherent poses for 21 out of the 36 hIKK-2 inhibitors assayed.
Then, a visual inspection of the chemical features involved in the
intermolecular interactions between hIKK-2 and these 43 poses
was used to identify those common to most of them and which,
therefore, could be used to build a common pharmacophore
describing the mechanism of the ligand-target interaction. The
resulting common structure-based pharmacophore, shown in
Figure 2B, contains one hydrogen-bond acceptor, two hydrogen-
bond donors and one hydrophobic site that were common to most
of the 43 poses. The spatial location of the hydrogen-bond donors
and acceptor sites was nearly coincident for all poses, but this was
not the case for the hydrophobic site that occupies a large volume
in the ATP-binding site. Thus, in the context of the common
structure-based pharmacophore, this was translated into a larger
radius for the hydrophobic feature (i.e., 3.0 A ˚) than for the
acceptor and donor radii (i.e., 1.5 A ˚), as a consequence of the huge
structural variability found for the inhibitor moieties that bound to
the narrow hydrophobic pocket located between the two hIKK-2
lobes (see Figure 2A). Moreover, to increase the power of the
pharmacophore to discriminate between hIKK-2 inhibitors and
inactive ligands that could adopt poses that accomplish the
pharmacophore features, a shell of excluded volumes was added
that schematically represents the locations of the residues forming
the ATP-binding site in our hIKK-2 homology model (see
Figure 2B). These excluded volumes were especially useful during
the second step of the VS workflow (see Figure 3), i.e., the
identification of molecules having at least one conformer that,
irrespective of its initial spatial orientation, can fit into the
pharmacophore (because this shell can be used to exclude from the
VS those inactive molecules that have at least one conformer that
matches the sites in the pharmacophore but is sterically hindered
by other residues in the binding site).
Virtual-screening workflow: validation and application to
the NP subset of the ZINC database
The capacity of our VS workflow to distinguish between hIKK-
2 inhibitors and molecules that do no inhibit hIKK-2 was
evaluated by applying it to a set consisting of 62 known hIKK-2
inhibitors (different from the 36 used during the structure-based
pharmacophore generation; see Table S2) and 10,036 kinase
decoys obtained from the Directory of Useful Decoys (DUD;
http://dud.docking.org) [46]. Figure 3 shows how many actives
and decoys survived each VS step. Thus, the ADME/Tox, the
pharmacophore-docking-pharmacophore and the shape and
electrostatic-potential comparison filters produced enrichment
factors of 1.4, 6.3 and 4.5, respectively, with a global enrichment
factor of 39.3 for the full VS process. Therefore, these results show
that our VS protocol is sufficiently selective to discern between
those molecules that can inhibit hIKK-2 from those that do not
affect its activity. Consequently, it was used to predict that 1,061
out of the 89,425 molecules in the ZINC Natural Products
Database were potential hIKK-2 inhibitors (see Figure 3).
Finding new scaffolds for hIKK-2 inhibitors
One of the most important challenges of any VS workflow is its
ability to find molecules with the required activity but without
trivial similarity (in terms of chemical structure) to known active
compounds. Thus, to determine which of the 1,061 potential
hIKK-2 inhibitors predicted by our VS workflow could be
considered as new lead molecules that may be of use in drug
design and development, we merged these 1,061 NPs with the 98
known hIKK-2 inhibitors used either for validation or for
pharmacophore-generation purposes, and the resulting set was
classified into clusters (data not shown). Notably, three out of the
ten clusters obtained consisted exclusively of NPs (i.e., Clusters 1, 2
and 3 contain 120, 88 and 38 NPs, respectively) and, therefore,
these 246 molecules are scaffold-hopping candidates for hIKK-2
inhibition (see Table S3). To prove the reliability of our
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ZINC01669260 and ZINC16946275 from Cluster 1; ZINC0-
3683886 from Cluster 2; and ZINC03871389 from Cluster 3; see
Figure 4) and tested their effects on the hIKK-2 activity using an in
vitro assay (see Figure 5). The results of this experiment showed that
three out of the five molecules (i.e., ZINC01669260 from Cluster 1,
ZINC03683886 from Cluster 2 and ZINC03871389 from Cluster
3) inhibited hIKK-2, with IC50 values ranging from 183.8 to
3,325 mM. Thus, the highest inhibition rate achieved for
ZINC03871389 (ethacridine, ethodin or rivanol) was 93% at a
15-mM inhibitor concentration. Similarly, the highest inhibition
rates achieved for ZINC01669260 (lupinine) and ZINC03683886
were 91 and 92% at 10- and 15-mM inhibitor concentrations,
respectively. Remarkably, a SciFinder search (Chemical Abstracts
Service, Columbus, Ohio, USA; http://www.cas.org/products/
sfacad) of the literature in which the three active molecules are
cited revealed that none of them have been described as anti-
inflammatory drugs. Therefore, this result supports the ability of
the electrostatic-potential and shape comparison performed by
EON to smooth differences in chemical structures and translate
them into criteria important for their intermolecular interactions
with the ligand-binding site (see Figure 6).
Structural analysis of the inhibition of hIKK-2 by
ZINC01669260, ZINC03683886 and ZINC03871389
The docking of ZINC01669260, ZINC03683886 and ZINC03-
871389 in the ATP-binding site of our hIKK-2 model showed that
the three molecules share the same form of intermolecular
interaction with the enzyme because they match the structure-
based common pharmacophore in the same orientation (see
Figure 7A) and because they form a hydrogen bond with the
carbonyl oxygen of the gk+3 residue (i.e., Cys99; see Figure 7B, 7C
and 7D; Cys99 also uses its backbone nitrogen to make a second
hydrogen bond with ZINC01669260; Figure 7C). Moreover,
ZINC03871389 and ZINC03683886 also interact with the side-
chain oxygen from Asp103 (see Figure 7B and 7D), and only
ZINC03871389 is able to form a third hydrogen bond with the
main-chain oxygen from the gk+1 residue (i.e., Glu97; see
Figure 7B). With respect to the hydrophobic interactions, they
were only detected for ZINC03871389 and ZINC03683886 (see
Figure 7B and 7D) and involve the acridine moiety of
ZINC03871389 (which interacts with Val29, Ala42, Val152 and
Ile165) and the methyl group from ZINC03683886 (which
interacts with Val29, Ala42, Val74, Val152 and Ile165). Notably,
our results show that there is a direct correlation between the
number and strength of intermolecular interactions and the
inhibitory activity of the three molecules. Thus, ZINC03871389,
ZINC03683886 and ZINC01669260 make three/four, two/five
and one/zero hydrogen bonds/hydrophobic interactions with key
residues on the hIKK-2 ATP binding pocket, and their
corresponding IC50 values are 183.8, 2,074 and 3,325 mM,
respectively.
Conclusions
The challenge of any VS protocol consists of using in silico tools
to predict which of the molecules in a database have the required
activity against a specific target. Thus, the results of the present
study demonstrate that our VS protocol successfully identified
hIKK-2 inhibitors with no chemical-structure similarities to
known actives and, therefore, it is suitable for scaffold hopping
on this target. Moreover, this is the first time that anti-
inflammatory activity has been described for ZINC03683886,
lupinine (i.e., ZINC01669260) and ethodin (i.e., ZINC03871389; a
molecule that is known to cause uterine contractions [59,60] and
that has been also described as inhibitor of the human
carboxylesterase 1 [61]). In this sense, the results of the present
study outperform those of a recent in silico survey on the ChemDiv
database (http://us.chemdiv.com) that found hIKK-2 inhibitory
activity for only two out of 29 hits selected for in vitro testing the VS
workflow success rate [42]. Moreover, one of these two molecules
shares the same core scaffold with BMS-345541 (a well-known
hIKK-2 inhibitor) [62] and, therefore, only the other molecule can
Figure 3. The VS workflow used in the present work. The data beside each VS step show the number of molecules that survived it. The ACTIVES
and DECOYS columns refer to known hIKK-2 and kinase decoys used during VS validation, respectively. The ZINC NPs column refers to data obtained
with the ZINC NP subset (http://wiki.compbio.ucsf.edu/wiki/index.php/Natural_products_database). Enrichment factors were calculated during the
validation of each step of the VS protocol as the quotient between the fraction of actives in the sample that survived the VS step and the fraction of
actives in the sample before the VS step.
doi:10.1371/journal.pone.0016903.g003
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hIKK-2 inhibitors.
Furthermore, although the pIC50 of the three hit molecules
that showed in vitro activity is significantly lower than that for
most known hIKK-2 inhibitors used in the present study (see
Tables S1 and S2), it is important that these three molecules (a)
can be used as lead compounds for developing more potent
inhibitors using structural-activity relationship studies and (b)
were selected based on their commercial availability, cost and
purity and with the primary goal of testing the performance of
our VS protocol. Therefore, it is possible that there are other
molecules in the remaining 241 included in Clusters 1, 2 and 3
(see Table S3) that show higher activity towards hIKK-2 than
ZINC03871389, ZINC03683886 and ZINC01669260 and could
be better lead compounds for drug development than these three
molecules. In this sense, our results indicate that the activity
correlates well with the ET_combo score provided by EON (see
Figure 4 and Table S3) and, therefore, this finding suggests that
molecules with ET_combo values higher than 1.2 (e.g.,
ZINC12410246, ZINC00485744 and ZINC00071662 from
Clusters 1, 2 and 3, respectively) are optimal starting points for
the rational drug design of potent and selective hIKK-2 inhibitors
with new chemical scaffolds.
Supporting information
Details on hIKK-2 synthetic inhibitors used in the present work
are described in Table S1 (for pharmacophore-generation
purposes) and S2 (for validation purposes). Table S3 reports the
ZINC codes for the 246 hit molecules that are predicted to inhibit
hIKK-2 and that are scaffold-hopping candidates for hIKK-2
inhibition, because the Tanimoto similarities between their
MOLPRINT 2D fingerprints and those from the hIKK-2
inhibitors in Table S1 and S2 are significantly low.
Methods
Homology-model building of the 3D-structure for the
kinase domain of hIKK-2
The sequence of hIKK-2 was obtained from the UniProt
database (http://www.uniprot.org, accession number O14920).
The protein templates used to build its homology model were PDB
structures that simultaneously satisfied the following criteria: (a)
highest sequence similarity with hIKK-2, (b) X-ray-derived
structures with acceptable quality (i.e., resolution ,2.50 A ˚ and
R-value,0.210 A ˚), (c) complexation with inhibitors that bind to
the ATP-binding site (because we were interested in the activated
Figure 4. 2D structures of the VS hits for which hIKK-2-inhibition activity was tested in an in vitro assay. The IC50 and pIC50 values are
also shown for those molecules that inhibit hIKK-2 and were calculated with GraphPad Prism v4.0.
doi:10.1371/journal.pone.0016903.g004
Figure 5. Dose-response results for the in vitro inhibition of
hIKK-2 by ZINC01669260, ZINC03683886 and ZINC03871389
(with n=3). The figure was drawn with GraphPad Prism v4.0.
doi:10.1371/journal.pone.0016903.g005
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PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16903form of our templates), (d) closest proximity to hIKK-2 [63] in the
human kinome tree (although IKK-2 is a serine/threonine kinase
without a defined family in this tree), and (e) structures with no
mutations in the active site of the kinase domain. The two kinases
that fulfilled these criteria and were thus chosen as templates
belong to the CAMK kinase family [63], have a 32% sequence
identity with the kinase domain of hIKK-2, have a 50% identity
with the residues of the ATP-binding site of hIKK-2 (where these
residues correspond to those in the G-loop, hinge region, HRD
motif and catalytic loop); they are the serine/threonine-protein
kinase CHK2 (PDB code 2CN5 [56]) and the death-associated
protein kinase 3 or ZIP kinase (PDB code 2J90 [57]). The
superposition of both template structures revealed some differenc-
es in their loop structures: (a) the G-loop is more open in 2J90
than in 2CN5 and (b) the A-loop coordinates were not present for
2J90. Armed with this information and following a knowledge-
based approach, we used MODELLER v9.5 [64] to align the
sequences and construct several models by changing their
alignments with the kinase domain of hIKK-2. The resulting
models were subsequently refined with MODELLER in a two-step
Figure 6. EON results for the best comparison between known hIKK-2 inhibitors and ZINC01669260, ZINC03683886 and
ZINC03871389. The best electrostatic-potential and shape comparisons between the docked poses from ZINC01669260, ZINC03683886 and
ZINC03871389 and those from the known hIKK-2 inhibitors used by EON as the queries of the last VS filter. For clarity, only the electrostatic potential
fields are shown. This Figure was drawn with VIDA v4.03 (OpenEye Scientific Software, Inc., Santa Fe, New Mexico, USA; http://www.eyesopen.com).
doi:10.1371/journal.pone.0016903.g006
Figure 7. Glide XP results for ZINC01669260, ZINC03683886 and ZINC03871389. Glide XP results for ZINC01669260, ZINC03683886 and
ZINC03871389 in the context of the structure-based common pharmacophore (panel A) and the hIKK-2 ATP-binding site (panels B, C and D). Thus,
Figure 7A shows that Glide XP was able to find at least one pose for ZINC01669260, ZINC03683886 and ZINC03871389 that matched the
pharmacophore. The intermolecular interactions of these poses with the hIKK-2 homology model are shown in Figure 7B (ZINC03871389), 7C
(ZINC01669260) and 7D (ZINC03683886). Hydrophobic contacts and hydrogen-bond donors/acceptors are shown as yellow spheres and red/green
arrows, respectively.
doi:10.1371/journal.pone.0016903.g007
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templates following an ab initio methodology [65], and a-helices
were the refined when loop processing was finished using the
templates) and using default running conditions. Next, the quality
of the resulting models was evaluated by (a) assessing the packing
quality with the Atomic Non-Local Environment Assessment
(ANOLEA) webserver (http://protein.bio.puc.cl/cardex/servers/
anolea) [66], (b) analyzing the outliers in the Ramachandran plot;
(c) examining the ATP-binding site structure (because it must be
optimized to built a receptor-based pharmacophore), and (d)
performing a protein-ligand rigid-docking study with the eHiTS
v2009 [67] software (SimBioSys Inc., Toronto, Canada; http://
www.simbiosys.ca/ehits) using various known hIKK-2 inhibi-
tors[47,48] and visually analyzing the knowledge-based coherence
of the results. In this sense, the capability of eHiTS to predict a
knowledge-based coherent pose was assessed by redocking the two
complexes used as templates to obtain the homology models.
Thus, eHiTS predicted poses for the ADP and pyridone 6 with
root-mean-square deviations relative to their experimental poses in
2CN5 and 2J90 of 1.23 and 0.38 A ˚, respectively.
Structure-based pharmacophore generation
The best homology model obtained for the hIKK-2 kinase
domain was subsequently used as the receptor in a protein-ligand
docking with 36 known selective ATP-competitive inhibitors for
hIKK-2 from different chemical families (see Table S1)
[10,11,13,15,16,18,20–31]. The docking was done with eHiTS
v2009 [67] by considering the receptor to be a rigid body and the
ligands as flexible (i.e., free rotation was allowed around the single
bonds of the ligand). Default docking conditions were selected
except for the size of the sides of the cubic box encompassing the
ATP-binding pocket, which was increased from 10 A ˚ to 15 A ˚.
Thereafter, all subsequent protein-ligand dockings in this work,
either for validation or VS purposes, were performed with eHiTS
v2009 using the same running conditions, hIKK-2 area and
homology-model orientation. Glide XP v5.6 (Schro ¨dinger LLC.,
Portland, USA; http://www.schrodinger.com), running with
default conditions, was used to predict the poses of three NPs
that our VS workflow predicted as hIKK-2 inhibitors and for
which activity was confirmed by the in vitro assay.
The protein-ligand interactions of the poses obtained by the
docking process (a maximum of 32 poses per ligand) were analyzed
with LigandScout v2.03 (Inte:ligand GmbH, Vienna, Austria,
http://www.inteligand.com/ligandscout) [68]. Next, the poses that
satisfied the generic binding features of ATP-competitive kinase
inhibitors [45] [i.e., the formation of hydrogen bonds with the main
chain of residues in the hinge region (segment 96–99 in hIKK-2
sequence) and hydrophobic interactions with the hydrophobic
pocket of hIKK-2 (e.g. Val29, Lys44, Val152, and Ile65)] were
selected as knowledge-based coherent (regardless of their eHiTS
scores). As a result of this analysis, 43 poses of the 21 hIKK-2
inhibitors were identified as knowledge-based coherent, and their
corresponding sites (i.e., functional groups used by the poses in their
intermolecular interactions with the hIKK-2 kinase domain) were
used to derive a common structure-based pharmacophore. This
pharmacophore contains one hydrogen-bond acceptor, two hydro-
gen-bond donors and one hydrophobic site common to most of the
43 poses. Moreover, the pharmacophore was completed with a shell
ofexcluded volumesthatschematicallyrepresentsthelocationofthe
residues forming the ATP-binding site in our hIKK-2 homology
model. This shell was built by applying the Receptor-Based Excluded
Volumes graphic front-end in Phase v3.1 (Schro ¨dinger LLC.,
Portland, USA; http://www.schrodinger.com) [69] to our hIKK-
2 kinase domain model and by setting the Sphere filters parameter
values to (a) ignore receptor atoms with surfaces within 0.25 A ˚ of the ligand
surface and (b) limit excluded-volume shell thickness to 10 A ˚.T h e
remaining parameters used in the front-end were the defaults.
Ligand setup
All the ligands used in this work (either for validation meth-
odology or for VS purposes) were processed in the same way. The
3D ligand structures were either downloaded from public databases
[i.e., DUD [46], the BindingDB (http://www.bindingdb.org) [47]
and the ZINC Natural Products Database (http://wiki.compbio.
ucsf.edu/wiki/index.php/Natural_products_database) [48]] or con-
structed with ChemDraw Ultra v11.0 (CambridgeSoft Corporation,
Cambridge, MA, USA; http://www.cambridgesoft.com) [70]. These
3D structures were then incorporated into LigPrep v2.3 (Schro ¨dinger
LLC., Portland, USA; http://www.schrodinger.com) and improved
by cleaning. The cleaning process was carried out with the following
parameters: (a) the force field used was OPLS 2005; (b) all possible
ionization states at pH 7.062.0 were generated with Ionizer; (c) the
desalt option was activated; (d) tautomers were generated for all
ionization states at pH 7.062.0; (e) chiralities, when present, were
determined from the 3D structure; and (f) one low-energy ring
conformation per ligand was generated. Conformations and sites for
the resulting ligand structures were determined during the generation
of the corresponding Phase [69] databases with the Generate Phase
Database graphic front-end. The parameter values used during this
conformer generation were by default with the exception of the
maximum number of conformers per structure, which was increased
from 100 (the default value) to 200. The conformer sites were
generated with definitions made by adding the ability to consider
aromatic rings as hydrophobic groups to the default built-in Phase
definitions.
Virtual-screening workflow
The NP subset of the ZINC database (http://zinc.docking.org/
vendor0/npd) [48] contains the 3D structure of 89,425 commer-
cially available NPs and NP derivatives and was used as the source
of molecules to which our VS schema was applied in the search for
new hIKK-2 inhibitors. Initially, these 89,425 molecules were
submitted to an ADME/Tox filter with the FAF-Drugs2 tool [71],
which aimed to discard molecules that either had poor ADME
properties or were potentially toxic. Thus, the drug-like properties
of a compound were evaluated using the Lipinski rule [72], and
only one violation of this rule was allowed. This rule is based on a
set of property values (i.e., the number of hydrogen-bond donors
and acceptors, the molecular weight and the logP) that were
derived from drugs with good ADME characteristics [72].
Therefore, molecules that pass the Lipinski rule are expected to
be active in humans after oral admission. Moreover, molecules
containing toxic groups were filtered using the 204 substructures
for ‘‘warhead’’ chelators, frequent hitters, promiscuous inhibitors
and other undesirable functional groups available in FAF-Drugs2
tool [71].
Molecules with appropriate ADME/Tox properties were then
set up with LigPrep and used to generate a Phase database. Next,
this database was filtered with Phase through the structure-based
common pharmacophore using the following running conditions:
(a) search in the conformers database, (b) do not score in place the
conformers into the structure-based common pharmacophore (i.e.,
allow reorientation of the conformers to determine if they match
the pharmacophore or not), (c) match at least three out of the four
sites of the structure-based common pharmacophore, (d) do not
consider any site as mandatory, (e) do not prefer partial matches
involving more sites and (f) use the excluded volumes from the
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parameter values used during that search were the default values.
Those ligands with at least one hit in this Phase search were
then docked to our hIKK-2 homology model. Then, the resulting
ligand poses were again filtered with Phase through the structure-
based common pharmacophore using the same filtering conditions
as in the first Phase run, with the exception that no reorientation of
the poses was allowed during the search (i.e., the score in place option
was used) to find docking poses that were compatible with the
pharmacophore.
Finally, the poses that were hits in this second pharmacophore
screening were submitted to a shape and electrostatic-potential
comparison with 43 poses from 21 known hIKK-2 inhibitors (see
Table S1) that (a) were also obtained by docking with our hIKK-2
homology model and (b) also matched the structure-based
common pharmacophore without reorientation. This comparison
was done with EON v2.0.1 (OpenEye Scientific Software, Inc.,
Santa Fe, New Mexico, USA; http://www.eyesopen.com) using
the ET_combo score as the similarity criterion. The ET_combo is the
sum of two calculations: (a) the Shape Tanimoto, which is a
quantitative measure of three-dimensional overlap [where 1
corresponds to a perfect overlap (i.e., the same shape)] [73] and
(b) the Poisson-Boltzman Electrostatic Tanimoto, which compares the
electrostatic potential of two small molecules (where 1 corresponds
to identical potentials and negative values correspond to the
overlap of positive and negative charges) [74]. Only those NPs
with ET_combo values equal to or greater than 0.850 were
considered as candidates for experimental tests of their activity on
hIKK-2.
Virtual-screening workflow validation
The ability of the VS workflow to identify hIKK-2 inhibitors in
a database of molecules was tested by applying the same filtering
method described for the NPs (i.e., the same methodology and
parameter values) to: (a) a group of 62 known inhibitors different
from the 36 used for the structure-based pharmacophore generation
(see Table S2) and (b) an external group of 10,139 kinase decoys
for Cdk2 and p38 (CMGC family at the human kinome tree [63])
that were obtained from DUD [46].
Hit selection for further experimental assays on hIKK-2
activity
A structural-similarity analysis of the NPs with ET_combo values
equal to or greater than 0.850 and all known hIKK-2 inhibitors
used in this work (either for validation or for pharmacophore-
generation purposes) was performed by executing a Schro ¨dinger
script that clusters molecules based on Tanimoto similarities
between MOLPRINT 2D fingerprints. We obtained ten clusters
and, notably, three of them consisted only of NPs. Thus, five
compounds from these three clusters were selected [based on their
commercial availability, cost and purity ($95%)] for experimental
assay of their effects on hIKK-2 activity. These compounds were
ZINC03683886, ZINC00242004 and ZINC03871389, bought
from InterBioScreen, Ltd (http://www.ibscreen.com), and
ZINC00058225 and ZINC01669260, bought from TimTec, Inc.
(http://www.timtec.net).
In vitro assay of the effect of selected compounds on the
hIKK-2 activity
The effect of the selected compounds on hIKK-2 kinase activity
was determined usingthe CalbiochemH K-LISA
TM IKKb Inhibitor
Screening Kit, designed for rapid in vitro screening of IKK-2
inhibitors. Briefly, the kit consists of an ELISA-based activity assay
that uses a 50-amino-acid GST-IkBa fusion-polypeptide substrate
that includes the Ser
32 and Ser
36 IKK-2 phosphorylation sites. The
GST-IkBa substrate and IKK-2 are incubated in the presence of
IKK-2 inhibitors in the wells of a glutathione-coated 96-well plate,
which allows for substrate phosphorylation and capture in a single
step. The phosphorylated GST-IkBa substrate is detected using an
anti-phospho-IkBa (Ser
32/Ser
36) antibody followed by an HRP-
conjugate and color development with the TMB substrate. The
ELISA stop solution is then used to stop the color development, and
the absorbance is read at 450 nm (with a reference wavelength of
540–600 nm). The absorbance is directly related to the IKK-2
activity level. Moreover, following the kit instructions, one positive
control and three negative controls were included by varying the
absence or presence of the commercial hIKK-2 inhibitor IV
(Calbiochem catalogue number: 401481), the ATP/MgCl2 mix and
the hIKK-2 enzyme. The results of these controls confirmed the
absence ofnonspecificor artificial inhibition.Three repetitions were
made for all the activity assays.
IC50 calculation
The potential of the molecules to inhibit hIKK-2 activity was
quantified by calculating their IC50 values. This parameter was
determined using GraphPad Prism v4.0 for Windows (GraphPad
Software, San Diego CA, USA; http://www.graphpad.com) by
fitting the experimental data from the in vitro assay to a nonlinear
regression function using a four-parameter logistic equation.
Supporting Information
Table S1 hIKK-2 inhibitors from different chemical families
docked with the hIKK-2 homology model. These 36 hIKK-2
inhibitors were docked with our hIKK-2 homology model without
imposing constraints that forced poses to make specific intermo-
lecular interactions with the target. Next, the resulting hIKK-2
complexes were analyzed with the help of LigandScout to
determine which complexes exhibited target-inhibitor intermolec-
ular interactions equivalent to those described in prior studies.
This knowledge-based analysis enabled us to identify at least one
knowledge-based coherent pose (43 in total) for 21 out of the 36
hIKK-2 inhibitors assayed (regardless of their scoring by eHiTS;
see their values in the Knowledge-based coherent docking poses column).
By analyzing the chemical features used by each pose in its
intermolecular interaction with hIKK-2, a common pharmaco-
phore was derived that describes the mechanism of the ligand-
target interaction. The Cluster column shows the cluster in which
each molecule was classified after running a Schro ¨dinger script
that clusters molecules based on Tanimoto similarities between
MOLPRINT 2D fingerprints (using the Knime v.2.0.3 module in
the Schro ¨dinger software package). The molecules distributed in
these clusters are the natural products obtained as hits in our
virtual-screening protocol and all known hIKK-2 inhibitors used
in the present work [either for validation (see Table S2) or for
pharmacophore-generation purposes]. The pIC50 values were
obtained from the literature.
(PDF)
Table S2 hIKK-2 inhibitors used during the validation of the
virtual-screening workflow. These 62 hIKK-2 inhibitors (different
from the 36 used during the structure-based pharmacophore
generation; see Table S1) were used to test the ability of the
virtual-screening workflow to identify hIKK-2 inhibitors in a
database of molecules. The Cluster column shows the cluster into
which each molecule was classified after running a Schro ¨dinger
script that clusters molecules based on Tanimoto similarities
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module in the Schro ¨dinger software package). The molecules
distributed in these clusters are the natural products obtained as
hits in our virtual-screening protocol and all known hIKK-2
inhibitors used in the present work (either for validation or for
pharmacophore-generation purposes). The pIC50 values were
obtained from the literature.
(PDF)
Table S3 Scaffold-hopping candidates for hIKK-2 inhibition
predicted by our study. The ZINC codes for the 246 hit
molecules predicted to inhibit hIKK-2 and belonging to clusters
consisting exclusively of natural products. For each hit molecule,
the best results of the shape and electrostatic-potential compar-
isons with 43 poses from 21 known hIKK-2 inhibitors (see Table
S1) is shown. Thus, the Tanimoto values for the comparison
between the electrostatic potentials of the molecules (using an
outer dielectric of 80) are shown in the PB columns, whereas the
values for the comparison between shapes are shown in the
Shape columns. The sum of the PB and Shape values is reported
in the Combo columns. Hits from each cluster are sorted
according their decreasing combo value. All of these hit
molecules are scaffold-hopping candidates for hIKK-2 inhibition
because the Tanimoto similarities between their MOLPRINT 2D
fingerprints and those from the hIKK-2 inhibitors in Tables S1
and S2 are quite low. ZINC00058225, ZINC01669260 and
ZINC16946275 from Cluster 1, ZINC03683886 from Cluster 2,
and ZINC03871389 from Cluster 3 were selected to experimen-
tally test the success rate of our predictions using an in vitro assay
(in bold in Table S3). The results of this experiment showed that
three out of the five molecules (i.e., ZINC01669260 from Cluster
1, ZINC03683886 from Cluster 2 and ZINC03871389 from
Cluster 3) inhibited hIKK-2, with IC50 values ranging from 183.8
to 3,325 mM.
(PDF)
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